Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Mednax (MD) Stock Price

News stories about Mednax (NYSE:MD) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mednax earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.032390042225 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Mednax (MD) remained flat at $$51.10 during trading hours on Friday. 2,120,000 shares of the company were exchanged, compared to its average volume of 1,860,000. The stock has a market cap of $4,790.00, a P/E ratio of 15.63, a price-to-earnings-growth ratio of 1.65 and a beta of 0.40. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.62. Mednax has a twelve month low of $40.56 and a twelve month high of $72.13.

Mednax (NYSE:MD) last announced its earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.87. The company had revenue of $868.95 million for the quarter, compared to analyst estimates of $864.78 million. Mednax had a return on equity of 10.80% and a net margin of 7.76%. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.09 earnings per share. equities analysts anticipate that Mednax will post 3.1 earnings per share for the current year.

Several research firms have recently weighed in on MD. Citigroup reduced their price objective on Mednax from $52.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, November 3rd. Jefferies Group reiterated a “hold” rating and set a $44.00 target price on shares of Mednax in a report on Friday, November 3rd. Robert W. Baird upped their target price on Mednax from $47.00 to $48.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. KeyCorp upgraded Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 target price on the stock in a report on Sunday, September 17th. Finally, Zacks Investment Research upgraded Mednax from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $53.70.

In related news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the sale, the insider now owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Cesar L. Alvarez sold 10,668 shares of the stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total value of $454,350.12. Following the sale, the director now directly owns 44,215 shares in the company, valued at approximately $1,883,116.85. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Mednax (MD) Stock Price” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Insider Buying and Selling by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply